Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
RPRX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 11, 2026
Report Source: 2026 1st Quarter Report
Royalty Pharma PLC. Stock Analysis RPRX
United States Health Care Large Cap Report: Royalty Pharma Plc engages in the provision of drug development services. The company is headquartered in New York City, New York and currently employs 100 full-time employees. The company went IPO on 2020-06-16. The company collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. The company funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
Read More Royalty Pharma PLC (RPRX) Chart
Key Statistics of Royalty Pharma PLC (RPRX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$53.58Volume
4.90MP/E Ratio (TTM)
41.2052 Week Range
Market Cap
30.84BAvg. Volume
4.57MDividend Yield
1.22%Financial Metrics & Statements of Royalty Pharma PLC (RPRX)
FAQ's for Royalty Pharma PLC (RPRX)
- According to Musaffa’s Shariah screening methodology, Royalty Pharma PLC (RPRX) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Royalty Pharma PLC using these criteria to determine its compliance status.
- Muslim investors may consider investing in Royalty Pharma PLC if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Royalty Pharma PLC by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Royalty Pharma PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Royalty Pharma PLC on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.